Nu Q Screening Triage Test receives CE mark approval in the EU for Colorectal Cancer diagnostics- VolitionRx

VolitionRx announced that the Company achieved CE marking on its Nu Q Colorectal Cancer Screening Triage Test, paving the way for its expected launch across the EU. The novel blood test, developed at Volition's laboratories in Belgium in conjunction with Hvidovre Hospital (University of Copenhagen), has demonstrated the potential to reduce colonoscopies by up to 25% while maintaining almost 97% detection of colorectal cancer when combined with the fecal immunochemical test (FIT) score. The Nu.Q Triage Test is the first in a pipeline of cancer screening tests that Volition hopes to bring to market.

The most frequently used first line test for colorectal cancer screening across Europe is the FIT test. Patients with a positive score following FIT are then referred for colonoscopy. However, approximately 94.8% of people who test FIT positive do not have colorectal cancer. This means that there are a significant number of unnecessary expensive and invasive colonoscopies performed, placing a severe burden on both the patient and the healthcare system. Now that it has achieved CE marking, European patients with a positive FIT score could subsequently be given the blood-based Nu Q Colorectal Cancer Screening Triage Test and then only be referred for colonoscopy if the combined test results indicate that it is necessary; thus potentially reducing colonoscopy referrals by up to 25%.